Bioventus Inc. (NASDAQ:BVS) Receives $14.25 Consensus PT from Analysts

Shares of Bioventus Inc. (NASDAQ:BVS) have been given an average rating of “Buy” by the five brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $14.25.

BVS has been the topic of several recent research reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bioventus in a research note on Monday, December 29th. Cantor Fitzgerald upgraded shares of Bioventus to a “strong-buy” rating in a research report on Wednesday, March 4th. Barrington Research raised their price target on Bioventus from $13.00 to $14.00 and gave the stock an “outperform” rating in a research report on Friday, March 6th. Finally, Craig Hallum upped their price objective on Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a report on Friday, March 6th.

Bioventus Stock Performance

Shares of BVS opened at $8.62 on Thursday. The company has a market capitalization of $716.75 million, a PE ratio of 26.12 and a beta of 0.78. Bioventus has a 52 week low of $5.81 and a 52 week high of $10.13. The company’s 50 day moving average price is $8.25 and its 200 day moving average price is $7.54. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.19 and a current ratio of 1.70.

Bioventus (NASDAQ:BVS) last released its quarterly earnings results on Thursday, March 5th. The company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.02. The firm had revenue of $157.90 million during the quarter. Bioventus had a return on equity of 28.88% and a net margin of 4.00%.Bioventus has set its FY 2026 guidance at 0.730-0.770 EPS.

Insider Activity

In other news, Director Michelle Mcmurry-Heath sold 12,000 shares of the company’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $8.79, for a total value of $105,480.00. Following the completion of the sale, the director directly owned 44,997 shares of the company’s stock, valued at $395,523.63. This represents a 21.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 33.00% of the company’s stock.

Institutional Investors Weigh In On Bioventus

Several large investors have recently bought and sold shares of BVS. Nantahala Capital Management LLC grew its stake in Bioventus by 4.1% in the fourth quarter. Nantahala Capital Management LLC now owns 6,047,403 shares of the company’s stock valued at $44,993,000 after acquiring an additional 236,741 shares during the period. Vanguard Group Inc. raised its holdings in shares of Bioventus by 4.4% in the third quarter. Vanguard Group Inc. now owns 2,924,788 shares of the company’s stock valued at $19,567,000 after purchasing an additional 122,749 shares during the last quarter. Royce & Associates LP raised its holdings in shares of Bioventus by 15.6% in the third quarter. Royce & Associates LP now owns 1,262,976 shares of the company’s stock valued at $8,449,000 after purchasing an additional 170,900 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Bioventus by 7.6% in the second quarter. American Century Companies Inc. now owns 1,124,041 shares of the company’s stock worth $7,441,000 after purchasing an additional 79,829 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Bioventus by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 1,120,238 shares of the company’s stock worth $8,337,000 after purchasing an additional 19,388 shares in the last quarter. Institutional investors own 62.94% of the company’s stock.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.